On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > BUSINESS
BUSINESS
- Astellas Files NDA for Prostate Cancer Treatment Enzalutamide in Japan
May 28, 2013
- “No Indication” of Data Manipulation in Diovan Studies: Novartis
May 27, 2013
- Bayer Launches Anticancer Treatment Stivarga
May 27, 2013
- 2012 Earnings: Foreign Pharmas’ Japan Units Underperform Market Growth, Operating Profit Down 21%
May 27, 2013
- Kyowa Kirin to Launch DPP-4 Inhibitor Onglyza in July Without Concurrent Use Restrictions
May 27, 2013
- OPF to Exclusively Market 3 Plasma Volume Expanders in Japan
May 24, 2013
- Daiichi Sankyo: Ranbaxy Former Shareholders Hid Critical Information
May 24, 2013
- Japan’s 1st Western Herbal Medicine Antistax to Hit Shelves in June: SSP
May 24, 2013
- Vital KSK HD Reports Single-Product, Single-Price Agreements Reached with Nearly 100% of Customers by End of March
May 24, 2013
- Pfizer Discontinues PIII Study of Inotuzumab Ozogamicin for NHL
May 24, 2013
- About 80% of Drug Makers Have Introduced Web Seminars; Cost-savings, Increased Sales Reported
May 24, 2013
- Maker FTC’s Provisional GL Prohibits Offering of Refreshments, Bentos at Web Seminars When There is Only 1 Participant from a Single Medical Institution
May 24, 2013
- Zeria Will Launch FD Treatment in June, Finding Patients Key, President Ibe Says
May 23, 2013
- Announcement: Sales Force Effectiveness Japan 2013 to Be Held on July 16, 17
May 23, 2013
- Meiji Seika Pharma’s Generic Sales Seen Reaching 30 Billion Yen a Year Ahead of Schedule
May 23, 2013
- Once-Monthly Injectable Abilify Reduces Total Psychiatric Hospitalization Rates following Disease Relapse: Otsuka, Lundbeck
May 23, 2013
- Efficacy of Major Depressive Disorder Treatment Vortioxetine Shown in Three of Four PIII Studies: Takeda and Lundbeck
May 23, 2013
- AZ Oncology Division to Provide Information Based on Patients’ Lifestyle
May 22, 2013
- Apo Plus Station Eyes Sales Force of 300 for Established Products
May 22, 2013
- Domestic Sales of Ethical Drugs Rose 0.3% to 9,560.1 Billion Yen in FY2012: IMS Japan
May 22, 2013
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…